医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MiraMed Continues Global Healthcare Expansion

2014年09月18日 AM02:37
このエントリーをはてなブックマークに追加


 

JACKSON, Mich.

MiraMed Global Services (MiraMed), headquartered in Jackson, Michigan, is pleased to announce the continuing global expansion of the MiraMed brand led by the success of its Big Data product in conjunction with MicroStrategy Incorporated and the ramping up of services and training in anticipation of the ICD-10 rollout. MiraMed, a full-service healthcare business process outsourcing (BPO) provider, has recently expanded facilities in its Chicago, IL regional office as well as expansions in its Manila, Philippines location and its expanded new locations in the Chennai, India region. New to the MiraMed family, the London, England office for MiraMed Global Services UK LLC was registered as a UK Establishment in the United Kingdom and offers reach to the European market. These expansions increase the footprint of MiraMed by nearly 150,000 square feet of newly-expanded space dedicated to the global healthcare environment.

The healthcare environment is changing rapidly worldwide, with healthcare reform in the United States and increased private delivery of health care in the United Kingdom, India and other countries. MiraMed, with its unparalleled data prowess and comprehensive revenue cycle platform, is ideally positioned to take advantage of this new global paradigm with the Big Data expertise to help you succeed.

Tony Mira, President and CEO of MiraMed states, “We live in a dynamic age where the availability of data is constantly growing.” Mira continues, “And collecting large amounts of data is ineffective without the proper tools to display and analyze those insights. MiraMed’s use of our proprietary Big Data product offers the ability to successfully interpret this data. Our tools help you understand the context of a specific metric, offering a smooth transition from the clinical, administrative and operational data sets to better understand the true messages that the data is trying to tell.”

Mira cautions, “This data explosion will continue into 2015 and beyond with the ICD-10 implementation, among others.” He continues, “Our approximately 1,000 experienced coders and nurses have received the highest level of training in anticipation of the ICD-10 rollout in 2015.” MiraMed stands ready with 4000+ employees to serve as your healthcare-focused BPO partner, with the technology, the infrastructure and the industry experts to ensure your success with the ICD-10 conversion and all your revenue cycle needs in October 2015 and beyond.

About MiraMed

Headquartered in Jackson, Michigan, MiraMed Global Services stands as the premier global provider of business process outsourcing solutions to healthcare organizations nationwide. MiraMed partners with hospitals, health networks, physician practices and related industry service organizations to provide a broad portfolio of customizable solutions, uncover and capitalize on hidden financial opportunities, improve productivity and ultimately increase profits.

MiraMed pairs healthcare industry experts with world-class processes, infrastructure and technology to deliver meaningful and measurable results. This proprietary model enables sustainable change by delivering a complete, customizable “end-to-end” solution devised to meet a client’s own unique financial and organizational needs.

If you would like more information about this topic, please go to www.miramedgs.com or email info@miramedgs.com.

https://www.facebook.com/miramedgs

https://twitter.com/miramedglobal

http://www.linkedin.com/company/miramed-a-global-services-company

https://plus.google.com/118286912392733358804/posts

CONTACT

MiraMed Global Services
Tony Mira, 517-787-7432
info@miramedgs.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表